{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:54Z","timestamp":1792819014682,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.seminhematol.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:19:57Z","timestamp":1744870797000},"page":"85-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom\u2019s Macroglobulinemia"],"prefix":"10.1053","volume":"62","author":[{"given":"Shayna","family":"Sarosiek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie L.","family":"Becking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanzaib","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.005_bib0001","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1182\/blood.V122.21.5090.5090","article-title":"Clinical characteristics and treatment outcome of CNS involvement (Bing-Neel syndrome) in waldenstrom's macroglobulinemia","volume":"122","author":"Kulkarni","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.005_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-025-06194-4","article-title":"Central nervous system involvement in waldenstrom macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation","volume":"104","author":"Ostergaard","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.005_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.13883","article-title":"Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study","volume":"172","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.005_bib0004","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","article-title":"Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"100","author":"Simon","year":"2015","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0005","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2024-206989","article-title":"Bing-Neel syndrome\u2014a case series of 46 patients from the United Kingdom","volume":"144","author":"Tomkins","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0007","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.1016\/S2152-2650(23)01350-2","article-title":"IBCL-099 intensive chemotherapy and autologous stem cell (ASCT) consolidation for Bing Neel syndrome","volume":"23","author":"Khwaja","year":"2023","journal-title":"Clin Lymph Myelom Leukem"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000310309","article-title":"Orbital involvement in Waldenstrom's macroglobulinemia: ultrasound, computed tomography and magnetic resonance findings","volume":"205","author":"Ettl","year":"1992","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.005_bib0009","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/WNO.0000000000000138","article-title":"Isolated optic nerve, chiasm, and tract involvement in Bing-Neel syndrome","volume":"34","author":"Hughes","year":"2014","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2310\/7070.2005.4112","article-title":"Skull base, orbital, and perineural involvement in Waldenstrom's Macroglobulinemia","volume":"35","author":"Karimi","year":"2006","journal-title":"J Otolaryngol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.005_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10792-007-9037-x","article-title":"Bilateral orbital tumor formation and isolated facial palsy in Waldenstrom's Macroglobulinemia","volume":"26","author":"Kumar","year":"2005","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.005_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/WNO.0b013e3181dee96c","article-title":"Orbital involvement in Bing-Neel syndrome","volume":"30","author":"Stacy","year":"2010","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.005_bib0013","first-page":"385","article-title":"Ophthalmic tumor formation in Waldenstrom's Macroglobulinemia","volume":"40","author":"Terasaki","year":"1996","journal-title":"Jpn J Ophthalmol"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.04.005_bib0014","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2169\/internalmedicine.0041-22","article-title":"The impact of tirabrutinib monotherapy for Bing-Neel syndrome in Waldenstrom's Macroglobulinemia","volume":"61","author":"Sekiguchi","year":"2022","journal-title":"Intern Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.005_bib0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.005_bib0016","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41375-025-02581-y","article-title":"Zanubrutinib in Bing Neel syndrome: efficacy and tolerability","volume":"39","author":"Becking","year":"2025","journal-title":"Leukemia"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.04.005_bib0017","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.04.005_bib0018","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.005_bib0019","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.14218","article-title":"Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome","volume":"179","author":"Mason","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0020","article-title":"A case of Bing-Neel syndrome successfully treated with ibrutinib","volume":"2018","author":"O'Neil","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0021","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12253-018-0482-9","article-title":"Standard dose of ibrutinib is effective in the treatment of Bing-Neel syndrome","volume":"26","author":"Plander","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226102","article-title":"First-line ibrutinib for Bing-Neel syndrome","volume":"2018","author":"Tallant","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.005_bib0023","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjh.20016","article-title":"Zanubrutinib for the treatment of Bing-Neel syndrome","volume":"206","author":"Sarosiek","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2024-211056","article-title":"Zanubrutinib is effective in the treatment of patients with Waldenstr\u00f6m's Macroglobulinemia and Bing-Neel syndrome: a retrospective multicenter study","volume":"144","author":"Undabeitia","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.005_bib0025","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/HS9.0000000000000155","article-title":"Efficacy of Zanubrutinib in the treatment of Bing-Neel syndrome","volume":"2","author":"Wong","year":"2018","journal-title":"Hemasphere"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.005_bib0026","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstrom's macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0027","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.04.005_bib0028","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.2169\/internalmedicine.9545-22","article-title":"Bing-Neel syndrome successfully treated with tirabrutinib","volume":"61","author":"Oyama","year":"2022","journal-title":"Intern Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.005_bib0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3960\/jslrt.22018","article-title":"Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation","volume":"62","author":"Saburi","year":"2022","journal-title":"J Clin Exp Hematop"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.005_bib0030","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1002\/ajh.24059","article-title":"Successful treatment with rituximab and bendamustine in a patient with newly diagnosed Waldenstrom's Macroglobulinemia complicated by Bing-Neel syndrome","volume":"90","author":"Varettoni","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0031","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0032","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory waldenstr\u00f6m macroglobulinemia: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstrom Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.005_bib0034","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.7150\/jca.81795","article-title":"Venetoclax penetrates the blood brain barrier: a pharmacokinetic analysis in pediatric leukemia patients","volume":"14","author":"Badawi","year":"2023","journal-title":"J Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.005_bib0035","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","article-title":"Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement","volume":"104","author":"Reda","year":"2019","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.04.005_bib0036","series-title":"Am Soc Hematol","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed \/refractory Waldenstr\u00f6m Macroglobulinemia: results from the phase 1\/2 BRUIN study","author":"Palomba","year":"2022"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.005_bib0038","doi-asserted-by":"crossref","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstrom macroglobulinemia: a preclinical model and initial clinical experience","volume":"10","author":"Palomba","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.005_bib0039","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-22-1682","article-title":"Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases","volume":"29","author":"Von Roemeling","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.04.005_bib0040","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood.V126.23.4004.4004","article-title":"Targeting IRAK1\/IRAK4 signaling in Waldenstrom's Macroglobulinemia","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.005_bib0041","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.005_bib0042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstrom's macroglobulinemia with BTK inhibitors","volume":"37","author":"Buske","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.005_bib0043","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:22:48Z","timestamp":1750843368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0037196325000150"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom\u2019s Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}